

NHSBT Board Tuesday 22nd July 2025

Title of Report	Business Continuity Policy		Agenda No.	4.2
Nature of Report	⊠ Official	□ Official Se	nsitive	
Author(s)	Tom Cowdrey, Head of Business Continuity			
Lead Executive	Helen Gillan, Director of Quality and Governance and Accountable Emergency Officer			
Non-Executive Director Sponsor	Ian Murphy, Chair of the Audit Risk and Governance Committee			
Presenter(s) at Meeting	Helen Gillan, Director of Quality and Governance			
Presented for		Information Update		
Purpose of the report and key issues				
NHSBT has had a Business Continuity Policy (POL137) since 2010, becoming a Board Level Policy (BPL8) as the Business Continuity Management System is a significant risk control and provides assurance which should be visible at all levels up to and including the Board. The purpose of this report is to gain approval for the Business Continuity Policy BLP8 which will supersede POL137. The purpose of the policy is to state the intention of NHS Blood and Transplant (NHSBT) to have a robust Business Continuity Management System (BCMS) certified to ISO22301 which ensures that the organisation can continue as far as reasonably practicable to maintain the supply of key products and services to the wider NHS in the event of a disruption.				
Previously Considered by				
Approved by the Risk Management Committee on 16 th June and by ARGC on 4 th July.				
Recommendation	The Board is asked to approve the p	olicy.		
Risk(s) identified (Link to Board Assurance Framework Risks)				
This paper outlines the Board Policy on Business Continuity and therefore affects any risk that uses Business Continuity as a control. This particularly relates to P-02 (Service Disruption) and P-03 (Service Disruption - Loss of Critical ICT), with a significant impact on P-04 (Donor Numbers & Diversity), which is listed as having service disruption as a primary impact. The policy ensures that the governance of NHSBT's Business Continuity Management System is at the appropriate level.				
Strategic Objective(s) this paper relates to:				
 □ Collaborate with partners □ Invest in people and culture □ Drive innovation □ Grow and diversify our donor base 				
Appendices:				